Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18073843 | 0.91 | LMNA (0.57) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL9604424 | 0.89 | ALDH1A1 (0.42) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL16248647 | 0.89 | ALDH1A1 (0.42) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL17589419 | 0.88 | ALDH1A1 (0.41) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL17860904 | 0.88 | LMNA (0.67) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL16217771 | 0.88 | LMNA (0.67) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL17448301 | 0.88 | LMNA (0.67) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL20828068 | 0.88 | LMNA (0.67) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL23069355 | 0.87 | LMNA (0.66) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL31400149 | 0.87 | LMNA (0.66) | LMNAKMT2APOLBCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | NOVO NORDISK A/S (DK) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | ADAR, NCL, SSU72 | LMNA 528/4885KMT2A 2367/4885POLB 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.